P089: Development and preliminary evaluation of a suicidal risk assessment protocol in a research trial using the Patient Health Questionnaire (PHQ-9).ECCO'24Year: 2024
Authors: Wileman, V.(1);McGuinness, S.(1);Sweeney , L.(1);Miller, L.(2);Stagg, I.(3);O@E@Carroll, R.(4);Moss-Morris, R.(1);Norton, C.(5)*;
(1)King@E@s College London, Psychology, London, United Kingdom;(2)Queen Mary University of London, Barts and the London Pragmatic Clinical Trials Unit PCTU, London, United Kingdom;(3)London North West Hospitals NHS Trust, St Mark@E@s Hospital The National Bowel Hospital and Academic Institute, London, United Kingdom;(4)University of Stirling, Psychology, Stirling, United Kingdom;(5)King@E@s College London, Florence Nightingale Faculty of Nursing- Midwifery & Palliative Care, London, United Kingdom;
P091: Single-cell metabolic phenotyping of monocytes and macrophages in Crohn’s diseaseECCO'24Year: 2024
Authors: Haag, L.M.(1)*;Lehmann, M.(1);Walling, S.(1);Kunkel, D.(2);Hecker, J.(1);Huck, A.(1);Glauben, R.(1);Weidinger, C.(1);Kuehl, A.A.(3);TRR241 IBDome Consortium, T.(1);Siegmund, B.(1);
(1)Charité - Universitätsmedizin Berlin, Department of Gastroenterology- Infectious Diseases and Rheumatology, Berlin, Germany;(2)Berlin Institute of Health BIH at Charité - Universitätsmedizin Berlin, BIH Flow & Mass Cytometry Core Facility, Berlin, Germany;(3)Charité - Universitätsmedizin Berlin, iPATH.Berlin – Core Unit Immunpathologie für Experimentelle Modelle, Berlin, Germany;
P093: Innovating in IBD care: what do patients and informal caregivers value? Preliminary results of a narrative inquiryECCO'24Year: 2024
Authors: Thomassen, B.J.M.(1,2,3)*;Hendrix, E.M.B.(1,3);Mujagic, Z.(1,3);Smeets, F.G.M.(1,4);de Jong, M.J.(5);Gevers, T.J.G.(1,3);Veldhuijzen, G.(6,7);Scherpenzeel, M.(8);Dijkstra, G.(9);Ament, S.M.C.(10);Pierik, M.J.(1,3);
(1)Maastricht University Medical Centre+, Department of Gastroenterology and Hepatology, Maastricht, The Netherlands;(2)Maastricht University Medical Centre+, Department of Surgery, Maastricht, The Netherlands;(3)Maastricht University, Research Institute for Nutrition and Translational Research in Metabolism NUTRIM, Maastricht, The Netherlands;(4)St. Jans Gasthuis, Department of Gastroenterology and Hepatology, Weert, The Netherlands;(5)Erasmus Medical Centre, Department of Gastroenterology and Hepatology, Rotterdam, The Netherlands;(6)Gelre Hospitals, Department of Gastroenterology and Hepatology, Apeldoorn, The Netherlands;(7)Radboud University Medical Centre, Department of Gastroenterology and Hepatology, Nijmegen, The Netherlands;(8)Crohn & Colitis Netherlands, crohn-colitis.nl, Woerden, The Netherlands;(9)University Medical Centre Groningen- University of Groningen, Department of Gastroenterology and Hepatology, Groningen, The Netherlands;(10)Maastricht University Medical Centre+, Department of Innovation - Centre of Expertise Quality- Innovation & Research, Maastricht, The Netherlands;
P095: Accelerated degradation of gut barrier-protecting 3-aminobenzoic acid exacerbate colitis in Inflammatory Bowel DiseaseECCO'24Year: 2024
Authors: Tanaka, M.(1)*;Toyonaga, T.(1);Nakagawa, F.(1);Sumiyoshi, N.(1);Shibuya, N.(1);Iwamoto, T.(2);Minemura, A.(3);Ariyoshi, T.(3);Matsumoto, A.(3);Oka, K.(3);Shimoda, M.(4);Saruta, M.(1);
(1)The Jikei University School of Medicine, Division of Gastroenterology and Hepatology- Department of Intenal Medicine, Tokyo, Japan;(2)The Jikei University School of Medicine, Division of Molecular Cell Biology- Core Research Facilities for Basic Science, Tokyo, Japan;(3)Miyarisan Pharmaceutical Co.- Ltd., Central Research Institute, Tokyo, Japan;(4)The Jikei University School of Medicine, Department of Pathology, Tokyo, Japan;
P096: Human extrachromosomal circular DNA is an emerging biomarker in Inflammatory Bowel DiseaseECCO'24Year: 2024
Authors: Petito, V.(1);DI VINCENZO, F.(1)*;Gerovska, D.(2);Piazzesi, A.(3);Russo, A.(4);Turchini, L.(1);Masi, L.(1);Lopetuso, L.R.(1);Abreu, M.T.(5);Regenberg, B.(6);Gasbarrini, A.(1);Putignani, L.(4);Bravo Araúzo, M.J.(7);Scaldaferri, F.(1);
(1)Fondazione Policlinico Universitario @D@A. Gemelli@D@ IRCCS- Università Cattolica del Sacro Cuore, Dipartimento di Medicina Interna e Gastroenterologia, Roma, Italy;(2)Biodonostia Health Research Institute, Computational Biology and Systems Biomedicine, San Sebastian, Spain;(3)Bambino Gesù Children’s Hospital- IRCCS, Multimodal Laboratory Medicine Research Area- Unit of Human Microbiome, Roma, Italy;(4)Bambino Gesù Children’s Hospital- IRCCS, Department of Diagnostic and Laboratory Medicine- Unit of Microbiology and Diagnostic Immunology- Unit of Microbiomics, Roma, Italy;(5)Miller School of Medicine- University of Miami, Division of Gastroenterology- Department of Medicine, Miami, United States;(6)University of Copenhagen, Department of Biology- SECTION FOR ECOLOGY AND EVOLUTION- Universitet sparken, Copenhagen, Denmark;(7)University of Basque Country UPV/EHU, Department of Cell Biology and Histology- Faculty of Medicine and Nursing, San Sebastian, Spain;
P097: Spatially resolved insights into fistulating Crohn@E@s disease pathogenesis: Unveiling molecular heterogeneityECCO'24Year: 2024
Authors: Mcgregor, C.(1,2)*;Yin, Z.(1);Bridges, E.(1);Gupta, T.(1,2);Aulicino, A.(1);Siejka-Zielinska, P.(1);Lee, C.H.J.(1,3);Bornschein, J.(1,2);Bignell, M.(2,4);George, B.(2,4);Vieth, M.(5,6);Tandon, R.(7);Fryer, E.(7);Antanaviciute, A.(1,3);Simmons, A.(1,2);
(1)University of Oxford, MRC Translational Immune Discovery Unit, Oxford, United Kingdom;(2)University of Oxford, Translational Gastroenterology Unit, Oxford, United Kingdom;(3)University of Oxford, MRC WIMM Centre for Computational Biology, Oxford, United Kingdom;(4)Oxford University Hospitals NHS Trust- John Radcliffe Hospital, Department of Colorectal Surgery, Oxford, United Kingdom;(5)Klinikum Bayreuth, Department of Pathology, Bayreuth, Germany;(6)Friedrich-Alexander University Erlangen-Nuremberg, Institute of Pathology, Oberfranken, Germany;(7)Oxford University Hospitals NHS Trust- John Radcliffe Hospital, Department of Cellular Pathology, Oxford, United Kingdom;
P098: The Endoscopic Severity Score Map (ESSM): An Artificial Intelligence scoring system providing accurate, objective and localised measurements of endoscopic disease severity in ulcerative colitis.ECCO'24Year: 2024
Authors: Gutierrez Becker, B.(1)*;Fraessle, S.(1);Yao, H.(2);Lüscher , J.(2);Girycki, R.(3);Machura, B.(4);Gośliński, J.(4);Czornik, J.(4);Pitura, M.(4);Arús-Pous, J.(1);Fisher, E.(5);Bojic, D.(6);Richmond, D.(2);Bigorgne, A.(5);Prunotto, M.(5);
(1)Roche, Pharma Research & Early Development. Data and Analytics, Basel, Switzerland;(2)Genentech Research and Early Development, Biological Research - AI Development, South San Francisco, United States;(3)Future Processing S.A., Future Processing S.A., Gliwice, Poland;(4)Graylight Imaging, Graylight Imaging, Gliwice, Poland;(5)Roche, Technology and Translational Research Product Development Immunology Infectious Diseases and Ophthalmology, Basel, Switzerland;(6)Roche, Product Development Clinical, Basel, Switzerland;
P099: Neutrophil extracellular traps enhance profibrotic activity of intestinal fibroblasts in Crohn@E@s disease through TLR2/NF-kB pathwayECCO'24Year: 2024
Authors: Dragoni, G.(1)*;Ke, B.J.(2);Picariello, L.(3);Ceni, E.(3);Mello, T.(3);Verstockt, B.(4);Abdurahiman, S.(2);Biscu, F.(2);Innocenti, T.(1);De Hertogh, G.(5);Martinod, K.(6);Galli, A.(3);Matteoli, G.(2);Vermeire, S.(4);
(1)Careggi University Hospital, Department of Gastroenterology- IBD Referral Centre, Firenze, Italy;(2)Translational Research Center for Gastrointestinal Disorders- Department of Chronic Diseases- Metabolism and Ageing- KU Leuven, Laboratory for Mucosal Immunology, Leuven, Belgium;(3)University of Florence, Gastroenterology Research Unit- Department of Experimental and Clinical Biochemical Sciences @D@Mario Serio@D@, Firenze, Italy;(4)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(5)KU Leuven- Faculty of Medicine, Laboratory of Translational Cell and Tissue Research- Department of Imaging and Pathology, Leuven, Belgium;(6)KU Leuven, Center for Molecular and Vascular Biology- Department of Cardiovascular Sciences, Leuven, Belgium;
P1000: A meta-analysis and systematic review of 5-aminosalicylates withdrawal in Inflammatory Bowel DiseaseECCO'24Year: 2024
Authors: Arzivian, A.(1);Kerkham, A.(2);Tran, Y.(3);Rubin, D.(4);Leong, R.(1)*;
(1)Macquarie University Hospital, Gastroenterology and Hepatology Department, Sydney, Australia;(2)Nepean Hospital, Gastroenterology and Hepatology Department, Sydney, Australia;(3)Macquarie University, Department of Health Sciences, Sydney, Australia;(4)University of Chicago, Inflammatory Bowel Disease Center, Chicago, United States;
P1001: Predictive factors of colectomy in patients admitted with Acute Severe Ulcerative ColitisECCO'24Year: 2024
Authors: Karpavičiūtė, V.(1)*;Kiudelis, G.(2);Kupčinskas, J.(2);Kupčinskas, L.(2);
(1)Hospital of Lithuanian University of Health Sciences Kaunas Clinics, Department of Gastroenterology, Kaunas, Lithuania;(2)Hospital of Lithuanian University of Health Sciences Kaunas Clinics, Department of Gastroenterology - Medical Academy, Kaunas, Lithuania;
P1003: Dietary pattern can influence the level of fatigue in patients with Inflammatory Bowel Disease in remissionECCO'24Year: 2024
Authors: Stroie, T.G.(1);Preda, C.M.(1)*;Istratescu, D.(1);Nitescu, M.(2);Manuc, T.E.(1);Manuc, M.(1);Meianu, C.G.(1);Andrei, A.(1);Ciora, C.A.(1);Louis, E.(3);Diculescu, M.M.(1);
(1)Fundeni Clinical Institute, Gastroenterology and Hepatology, Bucharest, Romania;(2)National Institute for Infectious Diseases Prof. Dr. Matei Bals, Infectious Diseases, Bucharest, Romania;(3)University Hospital CHU, Gastroenterology, Liège, Belgium;
P1004: Proportion of agents for refractory ulcerative colitis and the efficacy of immunomodulator in 5-aminosalicylic acid intoleranceECCO'24Year: 2024
Authors: Madarame, A.(1)*;Fukuzawa, M.(1);Naito, S.(1);Yamauchi, Y.(1);Yamaguchi, H.(1);Koyama, Y.(1);Kagawa, Y.(1);Ichimiya, T.(1);Shinohara, H.(1);Nemoto, D.(1);Itoi, T.(1);
(1)Tokyo Medical University Hospital, Gastroenterology and Hepatology, Tokyo, Japan;
P1005: Dose escalated Infliximab in Inflammatory Bowel Disease - Crohn@E@s Colitis Cure (CCC) Data Insights ProgramECCO'24Year: 2024
Authors: Alshiwanna, B.(1)*;Mcnamara, J.(1);Wilson, W.(2);Pipicella, J.L.(3);Ghaly, S.(4);Gearry, R.(5);Begun, J.(6);Williams, A.(1);Lynch, K.(7);Lawrance, I.(8);Schultz, M.(9);Walker, G.(10);Radford-Smith, G.(10);Connor, S.J.(1);Andrews, J.M.(7);
(1)Liverpool Hospital, Gastroenterology and Hepatology, Sydney, Australia;(2)Lyell McEwin Hospital, Anaesthetics, Adelaide, Australia;(3)Ingham Institure for Applied Medical Research, Gastroenterology and Hepatology, Sydney, Australia;(4)St Vincent@E@s Public & Private Hospitals, Gastroenterology and Hepatology, Sydney, Australia;(5)University of Otago, Department of Medicine, Christchurch, Australia;(6)Mater Hospital, Gastroenterology and Hepatology, Brisbane, Australia;(7)Central Adelaide Local Health Network, Gastroenterology and Hepatology, Adelaide, Australia;(8)St John of God Healthcare, Gastroenterology, Perth, Australia;(9)Dunedin Hospital, Gastroenterology and Hepatology, Dunedin, New Zealand;(10)Royal Brisbane and Women@E@s Hospital, Gastroenterology and Hepatology, Brisbane, Australia;
P1006: Assessing sexual health care needs in patients with inflammatory bowel diseaseECCO'24Year: 2024
Authors: Beattie, W.(1)*;Elford, A.(1);Segal, J.(1);Kaushik, V.(1);Downie, A.(1);Mitchell, J.(1);Al-Ani, A.(1);Prentice, R.(1);Christensen, B.(1);
(1)Royal Melbourne Hospital, Gastroenterology, Melbourne, Australia;
P1008: Efficacy and safety of retreatment with upadacitinib after treatment interruption in ulcerative colitis: Data from the phase 3 open-label extension study U-ACTIVATEECCO'24Year: 2024
Authors: Panaccione, R.(1)*;Colombel, J.F.(2);Dubinsky, M.(3);Hisamatsu, T.(4);Remple, V.(5);Garrison, A.(6);Klaff, J.(7);Kujawski, M.(8);Vermeire, S.(9);
(1)University of Calgary, Inflammatory Bowel Disease, Calgary, Canada;(2)Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States;(3)Icahn School of Medicine at Mount Sinai, Pediatric Gastroenterology, New York, United States;(4)Kyorin University School of Medicine, Department of Gastroenterology and Hepatology, Tokyo, Japan;(5)AbbVie Inc, Gastroenterology- Global Medical Affairs, Chicago, United States;(6)AbbVie Inc, Data & Statistical Sciences, Chicago, United States;(7)AbbVie Inc, Immunology Clinical Development, Chicago, United States;(8)AbbVie Inc, Immunology- Gastroenterology, Chicago, United States;(9)University Hospital Leuven, Gastroenterology and Hepatology, Leuven, Belgium;
P1009: Efficacy and safety of 4 years of continuous ozanimod treatment: an interim analysis of the True North open-label extension studyECCO'24Year: 2024
Authors: D@E@Haens, G.(1)*;Sands, B.E.(2);Ferrante, M.(3);Matsuoka, K.(4);Lindsay, J.O.(5);Blumenstein, I.(6);Mehra, D.(7);Charles, L.(7);Cetin, V.(7);Petersen, A.(7);Wu, H.(7);Wang, D.(8);Jain, A.(7);Hanauer, S.B.(9);
(1)Amsterdam University Medical Center, Gastroenterology, Amsterdam, The Netherlands;(2)Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States;(3)University Hospitals Leuven, Gastroenterology, Leuven, Belgium;(4)Toho University Medical Center- Sakura Hospital, Inflammatory Bowel Disease, Sakura, Japan;(5)Barts and the London School of Medicine and Dentistry, Immunobiology, London, United Kingdom;(6)Goethe University Hospital, Inflammatory Bowel Disease, Frankfurt, Germany;(7)Bristol Myers Squibb, n/a, Princeton, United States;(8)Bristol Myers Squibb K. K., n/a, Tokyo, Japan;(9)Northwestern University Feinberg School of Medicine, Crohn@E@s disease and Ulcerative Colitis, Chicago, United States;
P100: Salivary exosomes aggravate colitis via oral-gut axisECCO'24Year: 2024
Authors: Yang, C.(1)*;Chen, J.(1);Wu, J.(1);Zhao, Y.(1);Xu, Y.(1);You, P.(1);Xu, J.(1);Chen, N.(1);
(1)Peking University People’s Hospital, Department of Gastroenterology, Beijing, China;
